HP-505
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity.
HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity.
Pharmacology
The inhibitory effect of HP-505 on serotonin reuptake is approximately 1.8 and 3.5 times stronger than on norepinephrine and dopamine, respectively. Subsequent investigations have found that HP-505 acts on presynaptic dopamine transporters and is devoid of anticholinergic effects.
Synthesis
The N-methylated analog is called HP-365 [59142-29-9]. An older synthesis is available, although more modern methods exist now: patent:
Text derived from https://en.wikipedia.org/w/index.php?oldid=1339061481 under CC BY-SA 4.0; modifications have been made.